Editorial team
ioQuanta Research Desk
-
Evidence date ·What can happen to a discarded 3D print?
Review or Meta-AnalysisA 2021 review describes recycled PET that printed well, plus routes for clean reuse, reprocessing and chemical recovery that depend on the plastic.
-
Evidence date ·What should happen to a wind turbine blade as it ages?
Review or Meta-AnalysisA 2021 review explains why repair can extend a blade’s useful life, how recycling recovers materials, and why newer designs still face hurdles at large scale.
-
Evidence date ·Why adding an immune drug did not settle the chemotherapy choice
Review or Meta-AnalysisPooled immune-drug combinations showed better survival than platinum-etoposide in a 10-trial review; an indirect comparison with platinum-irinotecan found no clear edge.
-
Evidence date ·What can kidney inflammation during cancer care mean?
Review or Meta-AnalysisA 2021 oncology review compares drug-related kidney inflammation with infection and cancer-cell infiltration, showing why the cause can change care.
-
Evidence date ·What makes a tooth-colored filling wear down during use?
Review or Meta-AnalysisSome nanofilled composites resisted wear better in lab tests, but cited trials found no significant difference from conventional fillings in back teeth.
-
Evidence date ·When does a brain signal become usable for device control?
Review or Meta-AnalysisA 2021 review explains how sensors, control cues and calibration affect whether brain-controlled devices can respond reliably for different people and tasks.
-
Evidence date ·Could one engineered T cell target liver tumors and blood-vessel cells?
Peer-Reviewed PaperEngineered T cells killed CD105-rich liver-cancer and vessel-lining cells in lab tests, then slowed implanted liver tumors in two mouse models.
-
Evidence date ·What can a diagnosis code reveal about an immunotherapy reaction?
Review or Meta-AnalysisOf 174 patients with chart-identified reactions, 49 had no reflecting code and 31 had codes before treatment; 459 had suggestive codes but no chart-identified reaction.
-
Evidence date ·Can profiling bile duct tumors outside the liver sharpen the search for treatment?
Review or Meta-AnalysisA 2021 review finds potential drug targets in about one-quarter of extrahepatic bile duct tumors, while mixed-site trials make treatment results harder to interpret.
-
Evidence date ·What changed when immune checkpoint drugs joined cancer treatment?
Review or Meta-AnalysisA 19-trial review found better survival and response rates with added checkpoint drugs, while time to response showed no significant difference and severe side effects rose slightly.